Immune Checkpoint Inhibitor in Addition to Transurethral Resection of Bladder Cancer (TUBRT) and Radiation Therapy in Patients With cT2-4aN0M0 Bladder Cancer: a Mono-centre Clinical Study
Latest Information Update: 30 Dec 2022
At a glance
- Drugs Tislelizumab (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- Acronyms CBPTMI
Most Recent Events
- 26 Dec 2022 Planned End Date changed from 1 Oct 2025 to 1 Feb 2026.
- 26 Dec 2022 Planned primary completion date changed from 1 Oct 2023 to 1 Feb 2024.
- 26 Dec 2022 Planned initiation date changed from 1 Oct 2022 to 1 Feb 2023.